GeoVax Labs, Inc. (NASDAQ:GOVX) Receives $14.20 Consensus PT from Analysts

GeoVax Labs, Inc. (NASDAQ:GOVX) has been given a consensus recommendation of “Buy” by the seven brokerages that are currently covering the company, MarketBeat reports. Five research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. The average 12-month price objective among analysts that have issued a report on the stock in the last year is $14.20.

GOVX has been the subject of several research analyst reports. Alliance Global Partners assumed coverage on shares of GeoVax Labs in a research note on Monday, November 11th. They set a “buy” rating and a $15.00 target price for the company. D. Boral Capital restated a “buy” rating and set a $18.00 price target on shares of GeoVax Labs in a research note on Thursday, January 16th. Finally, HC Wainwright reiterated a “buy” rating and issued a $8.00 price objective on shares of GeoVax Labs in a report on Friday, November 15th.

GeoVax Labs Trading Down 6.3 %

NASDAQ GOVX opened at $1.94 on Friday. The business’s fifty day simple moving average is $2.42 and its 200-day simple moving average is $2.77. GeoVax Labs has a 52 week low of $1.09 and a 52 week high of $11.18.

GeoVax Labs (NASDAQ:GOVX) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($0.91) EPS for the quarter, beating analysts’ consensus estimates of ($1.29) by $0.38. The business had revenue of $2.79 million during the quarter, compared to analyst estimates of $1.84 million. During the same quarter in the prior year, the company posted ($4.80) earnings per share. As a group, sell-side analysts forecast that GeoVax Labs will post -4.49 EPS for the current fiscal year.

Institutional Investors Weigh In On GeoVax Labs

An institutional investor recently bought a new position in GeoVax Labs stock. Virtu Financial LLC purchased a new stake in GeoVax Labs, Inc. (NASDAQ:GOVX) in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 40,210 shares of the company’s stock, valued at approximately $97,000. Virtu Financial LLC owned approximately 0.43% of GeoVax Labs as of its most recent SEC filing. 6.09% of the stock is currently owned by institutional investors and hedge funds.

About GeoVax Labs

GeoVax Labs, Inc, a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers.